Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haptoglobin (HP)
- Target
- HP
- Molecular classification
- Other (acute-phase plasma glycoprotein)
01
Overview
Haptoglobin is an acute-phase plasma glycoprotein encoded by the HP gene, primarily produced by the liver but also by other tissues. Its main function is to bind free hemoglobin released from erythrocytes during intravascular hemolysis, thereby preventing oxidative damage and renal injury by facilitating clearance of the hemoglobin-haptoglobin complex via the CD163 scavenger receptor on macrophages[1][2][3][5][8]. Haptoglobin exhibits antioxidant and immunomodulatory activities and exists as different multimeric forms in humans due to genetic polymorphisms (mainly Hp1 and Hp2 alleles), which influence its hemoglobin-binding capacity and disease associations. Decreased haptoglobin is a key clinical biomarker for hemolytic anemia, and its genotypic variants are associated with cardiovascular and other disease risks[1][7][8].
- Other names
- Haptoglobin alpha chainHaptoglobin beta chainZonulinHP2ALPHA2HPA1SBPhaptoglobin binding peptidehaptoglobin alpha(1S)-betahaptoglobin alpha(2FS)-betahaptoglobin alpha polypeptidehaptoglobin beta polypeptidezonulin
02
Mechanism of action
Not applicable for direct drugs; as a biological molecule, haptoglobin's mechanism involves binding free hemoglobin to facilitate its clearance and prevent oxidative tissue damage
03
Biological functions
Hemoglobin binding and clearanceAntioxidant activity (inhibits hemoglobin-driven oxidative damage)Immune response/immunomodulationIron homeostasis
04
Disease associations
InflammationCardiovascular diseaseHemolytic disorders (e.g., hemolytic anemia)InfectionCancer (biomarker correlation shown in some cancers)
05
Safety considerations
Differences in haptoglobin genotype can affect antioxidant activity and susceptibility to oxidative stress-related diseasesNo direct drug therapy safety concerns related to haptoglobin targeting, but individuals with low haptoglobin can be at increased risk for kidney damage during hemolysis
06
Interacting drugs
None routinely clinically approved to target haptoglobin, but levels interact with free hemoglobin, which can be influenced by drugs causing hemolysis (e.g., certain chemotherapeutics, dapsone); haptoglobin itself is not directly targeted by marketed drugs
07
Biomarkers
Used in clinical assays to screen for and monitor intravascular hemolytic anemiaLow haptoglobin can serve as a marker for hemolysisInvestigated as a biomarker in cardiovascular and inflammatory disorders, and studied for roles in diabetes complications and cancer prognosis
Beyond the preview
Go deeper on Haptoglobin (HP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haptoglobin (HP).